U.S. officials have ordered Johnson & Johnson to stop using the single-dose corona vaccine following complaints of blood clots or thickening.
The US Drug Regulatory Authority, the Food and Drug Administration (FDA), approved the use of Johnson & Johnson’s single-dose vaccine at the end of February.
Compared to other vaccines, a single dose of the Johnson & Johnson vaccine was considered sufficient to prevent corona, and its use was approved by several European countries after the United States.
Another highlight of the Johnson & Johnson vaccine was that it could only be stored at room temperature for up to three months compared to other vaccines.
Although the results of this vaccine were less effective than other vaccines, experts believed that Johnson & Johnson was more effective than others due to its single dose.
Johnson & Johnson had provided US officials with 20 million doses by mid-March and promised to provide the remaining 100 million doses by June. However, a few weeks after the vaccine was used, orders were issued to stop its use immediately.
According to ‘Reuters‘ reported, the US Drug Regulatory Authority has banned hospitals and all vaccination centers from using the Johnson & Johnson vaccine.
According to the report, Johnson & Johnson’s use of the vaccine was stopped following complaints from people who had received the vaccine about blood clots or thickening.
The report quoted a New York Times report as saying that six people who received the Johnson & Johnson vaccine had complaints of severe blood clots, which led to a ban on its use.
The report said that out of the six people who complained of blood clots, one woman died while the other was rushed to the hospital in critical condition.
The vaccine also saw Johnson & Johnson’s market share fall by 3% following complaints of blood clots and cessation of its use.
Prior to Johnson & Johnson, other vaccines, including the Pfizer and Oxford University vaccines, had similar complaints in other parts of the world, and the vaccine was banned for a few weeks.